Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Gastric Cancer

Gastric Cancer

22 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Gastric Cancer

193 trials tracked for Gastric Cancer: 32 in phase 3 or 4 and 19 with published results. The most-cited published study has 1184 citations.

193Trials tracked
32Phase 3 & 4
0Recruiting
19With published results
Phase distribution
Phase 4 2 Phase 3 30 Phase 2 121 Phase 1 16 Other / NA 24
  1. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Completed · 1,184 cited
  2. Phase 3 Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Completed · 639 cited
  3. Phase 3 Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer Completed · 521 cited
  4. Phase 3 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Completed · 504 cited
  5. Phase 3 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer Completed · 480 cited
  6. Phase 3 Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer Completed · 356 cited
Show 44 more trials
  1. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) Completed · 352 cited
  2. Phase 3 Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Completed · 291 cited
  3. Phase 3 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Completed · 284 cited
  4. Phase 3 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Completed · 225 cited
  5. Phase 3 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer Completed · 220 cited
  6. Phase 3 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Completed · 130 cited
  7. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 112 cited
  8. Phase 3 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Completed · 99 cited
  9. Phase 3 Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer Completed · 77 cited
  10. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study Completed · 55 cited
  11. Phase 3 Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient Completed · 8 cited
  12. Phase 3 Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma Completed · 8 cited
  13. Phase 3 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Completed · 3 cited
  14. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  15. Phase 3 Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Completed
  16. Phase 3 A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer Completed
  17. Phase 3 A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Completed
  18. Phase 3 A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer Completed
  19. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension Completed
  20. Phase 3 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed
  21. Phase 3 A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma Completed
  22. Phase 3 A Safety and Efficacy Study in Patients With Gastric Cancer Completed
  23. Phase 3 ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer Completed
  24. Phase 3 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed
  25. Phase 3 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial Completed
  26. Phase 3 Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) Completed
  27. Phase 2 Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours Completed
  28. Phase 2 Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients Completed
  29. Phase 2 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer Completed
  30. Phase 2 Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer Completed
  31. Phase 2 RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment Completed
  32. Phase 2 Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT) Completed
  33. Phase 2 Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer Completed
  34. Phase 2 Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer Completed
  35. Phase 2 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer Completed
  36. Phase 2 Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer Completed
  37. Phase 2 A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. Completed
  38. Phase 2 Bupropion in Helping Adults Stop Smoking Completed
  39. Phase 2 IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer Completed
  40. Phase 2 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) Completed
  41. Phase 2 Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma Completed
  42. Phase 2 A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma Completed
  43. Phase 2 Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma Completed
  44. Phase 2 Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Completed

Showing the 50 most-cited and recently-updated of 193 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Gastric Cancer: what the trials found

Several immunotherapies demonstrated significant improvements in survival outcomes for patients with gastric cancer. Pembrolizumab showed statistically significant improvements in Overall Survival (OS) across multiple trials, including those involving specific biomarkers like PD-L1 CPS ≥ 10 [6, 19] and in combination with chemotherapy 11. Specifically, Pembrolizumab demonstrated a median OS of 15.7 months vs 11.8 months in patients with PD-1 CPS ≥ 10 6, and 12.0 months vs 5.3 months in the same cohort 19. In trials involving Nivolumab plus chemotherapy, significant improvements were noted in both OS (14.39 vs 11.10; p<0.0001) and Progression Free Survival (PFS) (7.69 vs 6.05; p<0.0001) for patients with PD-L1 CPS ≥ 5 15. Tislelizumab also showed significant improvements in OS for both PD-L1 positive participants 21 and the overall intent-to-treat population 21.

Other targeted and systemic therapies showed varying results. TAS-102 demonstrated a statistically significant improvement in Overall Survival (5.7 vs 3.6; p=0.0003) 7, while TAS-118 plus Oxaliplatin significantly improved OS, PFS, and Time to Treatment Failure compared to standard treatments 18. In contrast, Avelumab did not show statistically significant improvements in OS [8, 14] or other primary endpoints like ORR 8. Docetaxel (XRP6976) showed a statistically significant improvement in the percentage of participants with 3-year Progression-Free Survival (PFS) 10, while Ramucirumab demonstrated an Objective Response Rate (ORR) of 41.1% vs 36.4% 13.

Clinical outcomes for other interventions were less definitive or did not reach statistical significance in primary endpoints. Olaparib did not show a statistically significant difference in OS 12 or PFS 12, and the results for Objective Response were also not statistically significant 12. 5-Fluorouracil showed a non-significant trend in Overall Survival (p=0.0565) 9. Early palliative care did not result in a statistically significant change in Quality of Life scores at 12 or 24 weeks 16.

Recent results — preliminary, needs further review

  • Perioperative treatment is being evaluated in Phase 2 trials 1.
  • Trastuzumab BS is being evaluated in a Phase N/A trial 2.

For the clinician treating this condition

  • Pembrolizumab and Tislelizumab have demonstrated statistically significant improvements in Overall Survival across multiple studies, with Pembrolizumab showing particularly strong results in patients with high PD-L1 expression.
  • TAS-102 and the combination of TAS-118 plus Oxaliplatin showed statistically significant improvements in survival metrics (OS/PFS), whereas Avelumab did not show statistically significant improvements in OS.
  • Docetaxel (XRP6976) showed a statistically significant improvement in 3-year Progression-Free Survival, while other agents like Olaparib and 5-Fluorouracil did not reach statistical significance for primary survival outcomes.

AI synthesis of 15 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Bismuth quadruple and concomitant regimens achieve >85% H. pylori eradication amid rising clarithromycin resistance
Gastroenterology Sys. Review
Bismuth quadruple and concomitant regimens achieve >85% H. pylori eradication amid rising clarithromycin resistance H. pylori treatments failing as resistance grows, review finds
This narrative review synthesizes current H. pylori eradication strategies, noting that clarithromycin resistance exceeds 15%-20% in most re…
Clarithromycin resistance now tops 15-20% in most regions, but bismuth quadruple and other combos still clear the bug over 85% of the time.
Frontiers Jul 29, 2026
Zolbetuximab combined with chemotherapy improves progression-free survival and overall survival in CLDN18.2-expressing gastric cancers
Allergy & Immunology Meta-analysis
Zolbetuximab combined with chemotherapy improves progression-free survival and overall survival in CLDN18.2-expressing gastric cancers New drug shows promise for advanced stomach and esophageal cancer
This systematic review evaluates zolbetuximab in combination with chemotherapy for patients with advanced G/GEJ adenocarcinoma expressing hi…
A new treatment called zolbetuximab may improve survival rates for patients with specific types of advanced stomach and esophageal cancers.
Frontiers Jul 16, 2026
Metabolic reprogramming in the tumor microenvironment drives immune evasion and immunotherapy resistance in gastric cancer
Allergy & Immunology Sys. Review
Metabolic reprogramming in the tumor microenvironment drives immune evasion and immunotherapy resistance in gastric cancer How stomach cancer tricks the immune system to survive
This narrative review explores how metabolic crosstalk and nutrient competition within the tumor microenvironment influence immune suppressi…
Stomach cancer cells starve immune cells of nutrients and flood the area with waste, helping the tumor hide from treatment.
Frontiers Jul 9, 2026
Preoperative inflammatory and nutritional markers are associated with increased postoperative pulmonary risk in gastrointestinal cancers
Orthopedics & Sports Medicine Meta-analysis
Preoperative inflammatory and nutritional markers are associated with increased postoperative pulmonary risk in gastrointestinal cancers Inflammatory and Nutritional Markers Linked to Lung Risks After Surgery
This systematic review and narrative synthesis examines the association between preoperative biomarkers and postoperative pulmonary complica…
Poor nutrition and high inflammation levels before surgery may increase the risk of lung complications for patients with gastric or colorect…
Frontiers Jul 5, 2026
Machine learning models provide statistically significant improvements in 5-year survival prediction for gastric cancer patients
Oncology Meta-analysis
Machine learning models provide statistically significant improvements in 5-year survival prediction for gastric cancer patients AI Models Slightly Improve Gastric Cancer Survival Prediction
This systematic review and meta-analysis of 10 retrospective studies evaluated AI models using electronic health record data to predict 5-ye…
AI models modestly beat standard tools at predicting 5-year survival after gastric cancer surgery, a new meta-analysis finds.
Frontiers Jun 24, 2026
Serplulimab Combined With SOX Chemotherapy Improves Event Free Survival in Gastric Cancer
Oncology RCT
Serplulimab Combined With SOX Chemotherapy Improves Event Free Survival in Gastric Cancer Trial shows serplulimab improves outcomes for gastric cancer patients
Neoadjuvant serplulimab plus SOX chemotherapy significantly improves event-free survival and safety profiles for PD-L1-positive gastric aden…
A new clinical trial finds that adding the drug serplulimab to chemotherapy significantly extends event-free survival for certain types of s…
Jun 20, 2026
Enteral immunonutrition reduces infectious complications and hospital stay duration in gastric cancer surgery
Rheumatology Meta-analysis
Enteral immunonutrition reduces infectious complications and hospital stay duration in gastric cancer surgery Specialized Nutrition May Reduce Complications After Gastric Cancer Surgery
This meta-analysis of randomized controlled trials involving 1,653 patients found that enteral immunonutrition (EIN) significantly reduced i…
Patients undergoing gastric cancer surgery may experience fewer complications and shorter hospital stays when using a specific type of enric…
Frontiers Jun 17, 2026
Machine learning and postoperative indicators improve AUC for predicting anastomotic leak in gastric cancer surgery
Rheumatology Meta-analysis
Machine learning and postoperative indicators improve AUC for predicting anastomotic leak in gastric cancer surgery Machine Learning Models May Better Predict Gastric Cancer Complications
This systematic review and meta-analysis of 18 studies involving 15,783 patients evaluated risk prediction models for anastomotic leak. The …
New analysis shows machine learning models may offer better accuracy in predicting surgical complications for patients with gastric cancer.
Frontiers Jun 12, 2026
Signet ring morphology in gastric biopsies may mask metastatic invasive lobular carcinoma from breast cancer
Oncology Sys. Review
Signet ring morphology in gastric biopsies may mask metastatic invasive lobular carcinoma from breast cancer Expert Review Helps Identify Breast Cancer Spreading to Stomach
This case report describes a 52-year-old woman with metastatic invasive lobular carcinoma that was initially misidentified as primary gastri…
A single patient's case shows how specific lab tests can help doctors distinguish between stomach cancer and metastatic breast cancer.
Frontiers Jun 12, 2026
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models
Oncology Meta-analysis
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models Green tea compound shows potential for several digestive diseases
This meta-analysis of 63 preclinical studies involving 738 animals indicates that Epigallocatechin-3-gallate (EGCG) has a positive therapeut…
A review of animal studies suggests a green tea compound could help treat various cancers and digestive conditions.
Frontiers Jun 11, 2026
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Hematology Sys. Review
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Frontiers Jun 10, 2026
CIK/DC-CIK cell therapy plus chemotherapy improves overall survival in patients with gastric cancer
Oncology Meta-analysis
CIK/DC-CIK cell therapy plus chemotherapy improves overall survival in patients with gastric cancer Trial Shows CIK Cell Therapy Improves Survival in Gastric Cancer
This meta-analysis of 22 trials involving 2,149 patients found that CIK/DC-CIK cell therapy combined with chemotherapy significantly improve…
A review of clinical trials suggests that adding CIK or DC-CIK cell therapy to chemotherapy may improve survival for patients with gastric c…
Frontiers Jun 8, 2026

Questions about Gastric Cancer

Does CIK/DC-CIK cell therapy improve survival rates for gastric cancer?

Yes, CIK/DC-CIK cell therapy plus chemotherapy improves overall survival and disease-free survival in gastric cancer patients compared to chemotherapy alone.

Full answer →
Does EGCG have therapeutic effects on digestive system diseases like gastric cancer?

Yes, EGCG shows therapeutic effects against gastric cancer in lab and animal studies by inhibiting cell growth, inducing apoptosis, and altering immune signals, but human trials are lacking.

Full answer →
Can machine learning predict anastomotic leaks in gastric cancer patients?

Yes, machine learning models can predict anastomotic leaks in gastric cancer patients with good accuracy, especially when using postoperative indicators and immunonutritional indices.

Full answer →
Does enteral immunonutrition reduce infection risks after gastric cancer surgery?

Yes, enteral immunonutrition (EIN) reduces infection risks after gastric cancer surgery, with a 52% lower odds of infectious complications compared to standard enteral nutrition, especially when given for 7–10 days perioperatively.

Full answer →

All Gastric Cancer Articles